Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. shows strong potential for growth driven by faster than expected spine market expansion and increased sales in its Enabling Technologies segment, which could enhance overall profit margins. The company is currently trading below historical valuation levels, boasting impressive free cash flow (FCF) growth and an 8% FCF yield, which reinforces a favorable risk-reward scenario. Despite a recent earnings miss, the outlook remains positive with expectations for continued profit growth and resilience in the core business amid adverse market conditions.

Bears say

Globus Medical faces several critical risks that contribute to a negative outlook on its stock, including potential slower growth in the spine market, revenue dis-synergies from its merger with NuVasive, and disappointing sales within its Enabling Technologies segment. Fundamental concerns also arise from anticipated declines in operating margins and challenges related to key product launches and expansion efforts in the musculoskeletal space. As a result, revenue growth could decelerate to low-single digits, hindering margin expansion and overall financial performance.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.